Striatal and nigral COX-2 expression after chronic typical and atypical neuroleptic administration in rats

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 3, 2007, Pages 678-682

  Marin, C ^a   Saldana M ^a   Roca Ferrer, J ^a   Bonastre, M ^a   Aguilar, E ^a   Mullol, J ^a,b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Clozapine; Cyclooxygenases; Haloperidol; Neurodegeneration

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; CYCLOOXYGENASE 2; HALOPERIDOL; NEUROLEPTIC AGENT; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DOPAMINERGIC SYSTEM; LONG TERM CARE; MALE; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PROTEIN EXPRESSION; RAT; STATISTICAL SIGNIFICANCE; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; CORPUS STRIATUM; CYCLOOXYGENASE 2; GENE EXPRESSION REGULATION; MALE; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA;

EID: 33947600533     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.12.022     Document Type: Article

References (43)

1. Andreassen O.A., Ferrante R.J., Aamo T.O., Beal M.F., and Jorgensen H.A. Oral dyskinesias and histopathological alterations in substantia nigral after long-term haloperidol treatment of old rats. Neuroscience 122 (2003) 717-725
2. Aubin N., Curet O., Deffois C., and Carter C. Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J Neurochem 71 (1998) 1635-1642
3. Burger M.E., Fachinetto R., Wagner C., Perottoni J., Pereira R.P., Zeni G., et al. Effects of duphenyl-diselenide on orofacial dyskinesia model in rats. Brain Res Bull 70 (2006) 165-170
4. Chandrasekharan N.V., Dai H., Roos K.L., Evanson N.K., Tomsik J., Elton T.S., et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure and expression. Proc Natl Acad Sci U S A 99 (2002) 13926-13931
5. Dagalarrondo P., and Gattaz W.F. Basal ganglia abnormalities in tardive dyskinesia: possible relationship with duration of neuroleptic treatment. Eur Arch Psychiatry Clin Neurosci 24 (1994) 272-277
6. De Meira M., Braga A., Marques S., Bueno H., Tufik S., and Vital M.A.B.F. Different parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats. Brain Res 1101 (2006) 117-125
7. Feng Z.H., Wang T.G., Li D.D., Fung P., Wilson B.C., Liu B., et al. Cyclooxygenase-2-deficient mice are resistant to damage of dopaminergic neurons in the substantia nigra. Neurosci Lett 329 (2002) 354-358
8. Glazer W.M. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry 61 Suppl 4 (2000) 15-20
9. Hewett S.J., Uliasz T.F., Vidwans A.S., and Hewett J.A. Cyclooxygenase 2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture. J Pharmacol Exp Ther 293 (2000) 417-425
10. Hoozemans J.J., Veerhuis R., Janssen I., van Elk E.J., Rozemuller A.J., and Eikelenboom P. The role of cyclooxygenase 1 and 2 activity in prostaglandin E2 secretion by cultured human adult microglia: implications for Alzheimer's disease. Brain Res 951 (2002) 218-226
11. Hunot S., Vila M., Teismann P., Davis R.J., Hirsch E.C., Pzedborski S., et al. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 101 (2004) 665-670
12. Kane J.M. Tardive dyskinesia: epidemiology and clinical presentation. In: Bloom F.E., and Kupfer D.J. (Eds). Psychopharmacology: the fourth generation of progress vol. 39 (1995), Raven Press, New York 1485-1495
13. Kaufman W.E., Andreasson K.I., Isakson O., and Worley P.F. Cyclooxygenases and the central nervous system. Prostaglandins 54 (1997) 601-624
14. Kim E.J., Lee J.E., Know K.J., Lee S.H., Moon C.H., and Baik E.J. Differential roles of cyclooxygenase isoforms after kainic acid-induced prostaglandins E2 production and neurodegeneration in cortical and hippocampal cell cultures. Brain Res 908 (2001) 1-9
15. Knott C., Stern G., and Wilkin G.P. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci 16 (2000) 724-739
16. Kulkarni S.K., and Naidu P.S. Tardive dyskinesia: an update. Drugs Today 37 (2001) 97-119
17. Levinson A.J., Garside S., Rosebush P.I., and Mazurek M.F. Haloperidol induces persistent down-regulation of tyrosine hydroxylase immunoreactivity in substantia nigra but not ventral tegmental area in the rat. Neuroscience 84 (1998) 201-211
18. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 193 (1951) 265-275
19. Marchese G., Casu M.A., Bartholini F., Ruiu S., Saba P., Gessa G.L., et al. Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigrostriatal dopaminergic neurons directly related to "early onset" vacuous chewing. Eur J Neurosci 15 (2002) 1187-1196
20. Marchese G., Bartholini F., Ruiu S., Casti P., Casu G.L., and Pani L. Ritanserin counteracts both rat vacuous chewing movements and nigro-striatal tyrosine hydroxylase-immunostaining alterations induced by haloperidol. Eur J Pharmacol 483 (2004) 65-69
21. Marin C., Engber T.M., Bonastre M., Chase T.N., and Tolosa E. Effect of long-term haloperidol treatment on striatal neuropeptides: relation to stereotyped behavior. Brain Res 731 (1996) 57-62
22. Marin C., Bonastre M., and Tolosa E. Striatal c-fos levels do not correlate with haloperidol-induced behavioral supersensitivity. Synapse 23 (1996) 89-93
23. Mazurek M.F., Savedia S.M., Bobba R.S., Garside S., and Rosebush P.I. Persistent loss of tyrosine hydroxylase immunoreactivity in the substantia nigra after neuroleptic withdrawal. J Neurol Neurosurg Psychiatry 64 (1998) 799-801
24. Meshul C.K., Janowsky A., Casey D.E., Stalbaumer R.K., and Taylor B. Effect of haloperidol and clozapine on the density of "perforated" synapses in caudate, nucleus acumbens and medial prefrontal cortex. Psychopharmacology 106 (1992) 45-52
25. Meshul C.K., Stallbaumer R.K., Taylor B., and Janowsky A. Haloperidol-induced morphological changes in striatum are associated with glutamate synapses. Brain Res 648 (1994) 181-195
26. Mitchell I.J., Cooper A.C., Griffiths M.R., and Cooper A.J. Acute administration of haloperidol induces apoptosis of neurones in the striatum and substantia nigra in the rat. Neuroscience 109 (2002) 89-99
27. Naidu P.S., and Kulkarni S.K. Possible involvement of prostaglandins in haloperidol-induced orofacial dyskinesia in rats. Eur J Pharmacol 430 (2001) 295-298
28. Naidu P.S., and Kulkarni S.K. Differential effects of cyclooxygenase inhibitors on haloperidol-induced catalepsy. Prog Neuro-Psycopharmacol Biol Psychiatry (2002) 819-822
29. Ono N., Saito R., Abiru T., Kamiya H.O., and Tatsuo F. Possible involvement of prostaglandins in cataleptic behavior in rats. Pharmacol Biochem Behav 25 (1986) 463-471
30. Ono N., Saito R., Abiru T., Matsushita Y., and Kamiya H. Effect of aspirin on haloperidol-induced cataleptic behavior in mice. Neuropharmacology 27 (1988) 327-329
31. Ono N., Abiru T., Sugiyama K., and Kamiya H. Influence of cyclooxygenase inhibitors on the cataleptic behavior induced by haloperidol in mice. Prostaglandins Leukot Essent Fat Acids 46 (1992) 59-63
32. Przybylkowski A., Kurkowska-Jastrzebska I., Joniex I., Ciesielska A., Czlonkowska A., and Czlonkowski A. Cyclooxygenases mRNA and protein expression in striata in the experimental mouse model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to mouse. Brain Res 1019 (2004) 144-151
33. Rollema H., Skolnik M., D'Engelbronner J., Igarashi K., Usuki E., and Castagnoli Jr. N. MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies. J Pharmacol Exp Ther 268 (1994) 380-387
34. Rosenheck R., Cramer J., Xu W., Thomas J., Henderson W., Frisman K., et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study group on clozapine in refractory schizophrenia. N Engl J Med 337 (1997) 809-815
35. Sairam K., Saravanan K.S., Banerjee R., and Mohanakumar K.P. Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Res 966 (2003) 245-252
36. Saldaña M., Bonastre M., Aguilar E., and Marin C. Role pf NFkB p50 and p65 subunits expression in haloperidol-induced neurotoxicity and stereotyped behavior. Eur Neuropsychopharmacol 16 (2006) 491-497
37. Saldaña M, Bonastre M, Aguilar E, Marin C, (in press). Differential nigral expression of bcl-2 protein family in chronically haloperidol and clozapine-treated rats: Role in neurotoxicity and stereotyped behavior. Exp Neurol.
38. Sanchez-Pernaute R., Ferre A., Cooper O., Yu M., Brownell A.L., and Issacson O. Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J Neuroinflammation 1 (2004) 6
39. Teismann P., Tieu K., Choi D.K., Wu D.C., Naini A., Hunot S., et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci U S A 100 (2003) 5473-5478
40. Thomas D.M., and Kuhn D.M. Cyclooxygenase-2 is and obligatory factor in methamphetamine-induced neurotoxicity. J Pharmacol Exp Ther 313 (2005) 870-876
41. Ukai W., Ozawa H., Tateno M., Hashimoto E., and Saito T. Neurotoxic potential of haloperidol in comparison with risperidone: implication of Akt-mediated signal changes by haloperidol. J Neural Transm 111 (2004) 667-681
42. Vijitruth R., Liu M., Choi D.Y., Nguyen X.V., Hunter R.L., and Bing G. Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. J Neuroinflammation 3 (2006) 6
43. Yokoyama H., Kasai N., Ueda Y., Niwa R., Konaka R., Mori N., et al. In vivo analysis of hydrogen peroxide and lipid radicals in the striatum of rats under long-term administration of a neuroleptic. Free Radic Biol Med 24 (1998) 1056-1060